It can be concluded that ALDH1A1 inhibition, targeting primarily leukemia stem cells, could be combined with drugs that target non-stem cells, with the aim to eradicate both quiescent and proliferating AML cell fractions. The gene discussed is ALDH1A1; the disease is acute myeloid leukemia.